Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May;101(5):634-645.
doi: 10.1002/cpt.651.

Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment

T Yuraszeck  1 , S Kasichayanula  1 , J E Benjamin  2
Affiliations
Review

Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment

T Yuraszeck et al. Clin Pharmacol Ther. 2017 May.

Abstract

Bispecific T-cell Engagers (BiTE®) antibody constructs enable a polyclonal T-cell response to cell-surface tumor-associated antigens, bypassing the narrow specificities of T-cell receptors and the need for antigen presentation through the major histocompatibility complex pathways. Blinatumomab, a CD19xCD3 BiTE® antibody construct, received accelerated approval for the treatment of relapsed/refractory Philadelphia chromosome negative acute lymphoblastic leukemia. Herein we review the pharmacology, safety, and efficacy observed in studies of blinatumomab and other BiTE® antibody constructs. Quantitative systems pharmacology is envisioned as a means to optimize dosing decisions for trials in which BiTE® antibody constructs are administered as monotherapy or in combination with other immunotherapies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
From Coley Toxins to the Approval of Bispecific T‐Cell Engaging Antibody Constructs for Cancer Immunotherapy.
Figure 2
Figure 2
BiTE® antibody constructs promote T‐cell mediated target killing without the need for standard T‐cell recognition mechanisms.
Figure 3
Figure 3
Overview of clinical studies conducted to support blinatumomab approval.
See this image and copyright information in PMC

References

    1. Khalil, D.N. , Smith, E.L. , Brentjens, R.J. & Wolchok, J.D. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 13, 273–290 (2016). - PMC - PubMed
    1. Morrissey, K.M. , Yuraszeck, T.M. , Li, C.C. , Zhang, Y. & Kasichayanula, S. Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities. Clin. Transl. Sci. 9, 89–104 (2016). - PMC - PubMed
    1. Coley, W.B. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin. Orthopaed. Relat. Res. 262, 3–11 (1991). - PubMed
    1. McCarthy, E.F. The toxins of William B. Coley and the treatment of bone and soft‐tissue sarcomas. Iowa Orthopaed. J. 26, 154–158 (2006). - PMC - PubMed
    1. Ehrlich, P. Ueber den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Geneeskd 5, 273–290 (1909).

MeSH terms